VISTE
| Patologia: | Sarcomi dei tessuti molli |
| Area Tematica: | Oncologia |
| Data di Inizio Progetto: | 2026 |
| Data di Fine Progetto: | 2028 |
| Finanziamento: | € 472.200,00 |
| Partenariato | Istituto di Ricerche Farmacologiche Mario Negri IRCCS IRCCS Istituto Clinico Humanitas |
This project studies how the cancer drug Eribulin, used for soft tissue tumors, affects blood vessels in tumors. By using advanced imaging and tissue analysis, researchers aim to understand how these changes impact drug delivery and tumor behavior. The goal is to find ways to improve treatment and identify signs that predict how patients will respond.